{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:19:44Z","timestamp":1757618384723,"version":"3.44.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T00:00:00Z","timestamp":1750032000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T00:00:00Z","timestamp":1750032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s40120-025-00774-2","type":"journal-article","created":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T06:19:00Z","timestamp":1750054740000},"page":"1627-1639","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative Effectiveness of Fumarates Versus Sphingosine-1-Phosphate Receptor Modulators in Black Patients with Multiple Sclerosis"],"prefix":"10.1007","volume":"14","author":[{"given":"Sophia","family":"Woodson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward J.","family":"Gettings","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chu-Yueh","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0406-0460","authenticated-orcid":false,"given":"Sylvia","family":"Klineova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong-Mi","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca S.","family":"Romero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aljoeson","family":"Walker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Belviso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3249-8360","authenticated-orcid":false,"given":"Sai L.","family":"Shankar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2526-5542","authenticated-orcid":false,"given":"Jason P.","family":"Mendoza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0153-4218","authenticated-orcid":false,"given":"Boyang","family":"Bian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2352-9113","authenticated-orcid":false,"given":"James B.","family":"Lewin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kinyee","family":"Fong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,16]]},"reference":[{"unstructured":"MS International Federation. Atlas of MS. 2023. https:\/\/www.atlasofms.org\/map\/united-states-of-america\/epidemiology\/number-of-people-with-ms#about. Accessed 25 Sept 2024.","key":"774_CR1"},{"unstructured":"US Census Bureau. QuickFacts. 2023. https:\/\/www.census.gov\/quickfacts\/fact\/table\/US\/RHI225222. Accessed 25 Sept 2024.","key":"774_CR2"},{"key":"774_CR3","first-page":"8","volume":"11","author":"BE Turner","year":"2022","unstructured":"Turner BE, Steinberg JR, Weeks BT, Rodriguez F, Cullen MR. Race\/ethnicity reporting and representation in US clinical trials: a cohort study. Lancet Reg Health Am. 2022;11:8.","journal-title":"Lancet Reg Health Am."},{"issue":"11","key":"774_CR4","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s11910-019-1000-5","volume":"19","author":"VP Cipriani","year":"2019","unstructured":"Cipriani VP, Klein S. Clinical characteristics of multiple sclerosis in African-Americans. Curr Neurol Neurosci Rep. 2019;19(11):87.","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"2","key":"774_CR5","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1212\/CPJ.0000000000000112","volume":"5","author":"O Khan","year":"2015","unstructured":"Khan O, Williams MJ, Amezcua L, et al. Multiple sclerosis in US minority populations: clinical practice insights. Neurol Clin Pract. 2015;5(2):132\u201342.","journal-title":"Neurol Clin Pract"},{"issue":"3","key":"774_CR6","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1212\/WNL.0b013e3181e8e72a","volume":"75","author":"I Kister","year":"2010","unstructured":"Kister I, Chamot E, Bacon JH, et al. Rapid disease course in African Americans with multiple sclerosis. Neurology. 2010;75(3):217\u201323.","journal-title":"Neurology"},{"unstructured":"Tecfidera [prescribing information]. Biogen Inc., Cambridge, MA, 2024. https:\/\/www.tecfidera.com\/content\/dam\/commercial\/multiple-sclerosis\/tecfidera\/pat\/en_us\/pdf\/full-prescribing-info.pdf. Accessed 18 Dec 2024.","key":"774_CR7"},{"unstructured":"Vumerity [prescribing information]. Biogen Inc., Cambridge MA, 2024. https:\/\/www.vumerityhcp.com\/content\/dam\/commercial\/vumerity\/hcp\/en_us\/pdf\/vumerity-prescribing-information.pdf. Accessed 18 Dec 2024.","key":"774_CR8"},{"unstructured":"Novartis. Gilenya prescribing information. 2024. https:\/\/www.novartis.com\/us-en\/sites\/novartis_us\/files\/gilenya.pdf. Accessed 18 Dec 2024.","key":"774_CR9"},{"unstructured":"Novartis. Mayzent prescribing information. 2024. https:\/\/www.novartis.com\/us-en\/sites\/novartis_us\/files\/mayzent.pdf. Accessed 18 Dec 2024.","key":"774_CR10"},{"unstructured":"Janssen Pharmaceuticals. Ponvory prescribing information. 2023. https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/PONVORY-pi.pdf. Accessed 18 Dec 2024.","key":"774_CR11"},{"unstructured":"Bristol Myers Squibb. Zeposia prescribing information. 2024. https:\/\/packageinserts.bms.com\/pi\/pi_zeposia.pdf. Accessed 18 Dec 2024.","key":"774_CR12"},{"issue":"12","key":"774_CR13","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1007\/s00415-018-9083-5","volume":"265","author":"S Braune","year":"2018","unstructured":"Braune S, Grimm S, van Hovell P, et al. Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry. J Neurol. 2018;265(12):2980\u201392.","journal-title":"J Neurol"},{"issue":"5","key":"774_CR14","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s40263-023-01002-x","volume":"37","author":"T Jiang","year":"2023","unstructured":"Jiang T, Ziemssen T, Wray S, et al. Matching-adjusted indirect comparisons of diroximel fumarate, ponesimod, and teriflunomide for relapsing multiple sclerosis. CNS Drugs. 2023;37(5):441\u201352.","journal-title":"CNS Drugs"},{"issue":"10","key":"774_CR15","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2023-0161","volume":"13","author":"T Jiang","year":"2024","unstructured":"Jiang T, Shanmugasundaram M, Bozin I, et al. Comparative efficacy of diroximel fumarate, ozanimod and interferon beta-1a for relapsing multiple sclerosis using matching-adjusted indirect comparisons. J Comp Eff Res. 2024;13(10): e230161.","journal-title":"J Comp Eff Res"},{"key":"774_CR16","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.msard.2018.09.038","volume":"27","author":"D Ontaneda","year":"2019","unstructured":"Ontaneda D, Nicholas J, Carraro M, et al. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US. Mult Scler Relat Disord. 2019;27:101\u201311.","journal-title":"Mult Scler Relat Disord"},{"issue":"3","key":"774_CR17","first-page":"205521731772510","volume":"3","author":"B Vollmer","year":"2017","unstructured":"Vollmer B, Nair KV, Sillau SH, et al. Comparison of fingolimod and dimethyl fumarate in the treatment of multiple sclerosis: two-year experience. Mult Scler J Exp Transl Clin. 2017;3(3):2055217317725102.","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"3","key":"774_CR18","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s40120-023-00461-0","volume":"12","author":"J Perumal","year":"2023","unstructured":"Perumal J, Balabanov R, Balcer L, et al. Long-term effectiveness and safety of natalizumab in african american and hispanic\/latino patients with early relapsing-remitting multiple sclerosis: STRIVE data analysis. Neurol Ther. 2023;12(3):833\u201348.","journal-title":"Neurol Ther"},{"issue":"7","key":"774_CR19","first-page":"915","volume":"27","author":"A Burkhard","year":"2021","unstructured":"Burkhard A, Toliver J, Rascati K. Association between multiple sclerosis disease severity and adherence to disease-modifying therapies. J Manag Care Spec Pharm. 2021;27(7):915\u201323.","journal-title":"J Manag Care Spec Pharm"},{"issue":"3","key":"774_CR20","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s40120-022-00358-4","volume":"11","author":"W Zhu","year":"2022","unstructured":"Zhu W, Tang X, Heyman RA, et al. Patterns of utilization and expenditure across multiple sclerosis disease-modifying therapies: a retrospective cohort study using claims data from a commercially insured population in the United States, 2010\u20132019. Neurol Ther. 2022;11(3):1147\u201365.","journal-title":"Neurol Ther"},{"unstructured":"Komodo Health Inc. Komodo race & ethnicity data: user guide version V23.8. Komodo Health Inc., San Francisco; 2024.","key":"774_CR21"},{"issue":"16","key":"774_CR22","first-page":"2","volume":"88","author":"J Nicholas","year":"2017","unstructured":"Nicholas J, Ontaneda D, Carraro M, et al. Development of an algorithm to identify multiple sclerosis (MS) disease severity based on healthcare costs in a US administrative claims database (P2.052). Neurology. 2017;88(16):2.","journal-title":"Neurology"},{"key":"774_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102539","volume":"46","author":"J Toliver","year":"2020","unstructured":"Toliver J, Barner JC, Lawson K, Sonawane K, Rascati K. Replication of a claims-based algorithm to estimate multiple sclerosis disease severity in a commercially insured population. Mult Scler Relat Disord. 2020;46:102539.","journal-title":"Mult Scler Relat Disord"},{"key":"774_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.102741","volume":"49","author":"JC Toliver","year":"2021","unstructured":"Toliver JC, Barner JC, Lawson KA, Rascati KL. Use of a claims-based algorithm to estimate disease severity in the multiple sclerosis Medicare population. Mult Scler Relat Disord. 2021;49:102741.","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"774_CR25","doi-asserted-by":"publisher","first-page":"618","DOI":"10.3111\/13696998.2010.523670","volume":"13","author":"BJ Chastek","year":"2010","unstructured":"Chastek BJ, Oleen-Burkey M, Lopez-Bresnahan MV. Medical chart validation of an algorithm for identifying multiple sclerosis relapse in healthcare claims. J Med Econ. 2010;13(4):618\u201325.","journal-title":"J Med Econ"},{"key":"774_CR26","doi-asserted-by":"publisher","DOI":"10.54724\/lc.2022.e18","volume":"2","author":"SW Lee","year":"2022","unstructured":"Lee SW, Acharya KP. Propensity score matching for causal inference and reducing the confounding effects: statistical standard and guideline of Life Cycle Committee. Life Cycle. 2022;2:e18.","journal-title":"Life Cycle"},{"doi-asserted-by":"crossref","unstructured":"Woodson S, Gettings E, Guo C-Y, et al. Real-world treatment outcomes in Black, Hispanic, Asian, and White people with multiple sclerosis treated with fumarates (P4\u20136.005). Neurology. 2024;102(7):6308.","key":"774_CR27","DOI":"10.1212\/WNL.0000000000206384"},{"unstructured":"Woodson S, Gettings EJ, Guo C-Y, et al. Real world treatment outcomes in Black, Hispanic, Asian, and White people with multiple sclerosis treated with fumarates. In: ACTRIMS Forum, 29 February-2 March 2024, West Palm Beach; P479.","key":"774_CR28"},{"issue":"5","key":"774_CR29","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1056\/NEJMoa0909494","volume":"362","author":"L Kappos","year":"2010","unstructured":"Kappos L, Radue EW, O\u2019Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387\u2013401.","journal-title":"N Engl J Med"},{"issue":"12","key":"774_CR30","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/s41582-022-00735-5","volume":"18","author":"R Dobson","year":"2022","unstructured":"Dobson R, Rice DR, D\u2019Hooghe M, et al. Social determinants of health in multiple sclerosis. Nat Rev Neurol. 2022;18(12):723\u201334.","journal-title":"Nat Rev Neurol"},{"issue":"12","key":"774_CR31","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1185\/03007995.2013.847411","volume":"29","author":"N Bergvall","year":"2013","unstructured":"Bergvall N, Makin C, Lahoz R, et al. Comparative effectiveness of fingolimod versus interferons or glatiramer acetate for relapse rates in multiple sclerosis: a retrospective US claims database analysis. Curr Med Res Opin. 2013;29(12):1647\u201356.","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"774_CR32","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s40801-021-00251-w","volume":"8","author":"L Freeman","year":"2021","unstructured":"Freeman L, Kee A, Tian M, Mehta R. Retrospective claims analysis of treatment patterns, relapse, utilization, and cost among patients with multiple sclerosis initiating second-line disease-modifying therapy. Drugs Real World Outcomes. 2021;8(4):497\u2013508.","journal-title":"Drugs Real World Outcomes"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00774-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-025-00774-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00774-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T20:05:56Z","timestamp":1757189156000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-025-00774-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,16]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["774"],"URL":"https:\/\/doi.org\/10.1007\/s40120-025-00774-2","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"type":"print","value":"2193-8253"},{"type":"electronic","value":"2193-6536"}],"subject":[],"published":{"date-parts":[[2025,6,16]]},"assertion":[{"value":"12 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Sophia Woodson served on scientific advisory or data safety monitoring boards for MSSA and Sanofi, and served on speaker bureaus for Biogen, Bristol Myers Squibb, and Genentech. Edward J Gettings, Jong-Mi Lee, and Aljoeson Walker declare that they have no competing interests. Chu-Yueh Guo has received consulting fees from Genentech and Horizon. Sylvia Klineova has received consulting fees from Amgen and TG Therapeutics and for contracted research for Biogen, and served on speakers bureaus for Alexion and Biogen. Rebecca S Romero has received consulting fees from Alexion, EMD Serono, Genentech, Horizon, and TG Therapeutics. Nicholas Belviso, Sai L Shankar, Jason P Mendoza, Boyang Bian, James B Lewin, and Kinyee Fong are all employees of Biogen and may hold stock in the company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This study was a retrospective analysis of de-identified data from the Komodo Health Sentinel database and did not involve any new studies with human or animal subjects. As such, ethical approval or informed consent was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}